Organ support & nutrition

Renal outcomes following intravenous contrast administration in patients with acute kidney injury: a multi-site retrospective propensity-adjusted analysis

Intensive Care MedPublished Retrospective cohort study

Authors' conclusion

Among patients with pre-existing AKI, contrast administration was not associated with either persistent AKI at hospital discharge or initiation of dialysis within 180 days.

Study context

Population
Consecutive hospitalized adults (≥ 18 years) meeting Kidney Disease Improving Global Outcomes (KDIGO) creatinine-based criteria for acute kidney injury (AKI) on arrival to one of three EDs, 7/1/2017–6/30/2021
Participants
14,449 patient encounters
Exposure
Intravenous contrast media vs no contrast media
Outcome
Persistent AKI at hospital discharge
Follow-up
Hospital discharge
Methodological detailspropensity-weighted, entropy-balanced, multi-site
  • Propensity-weighted
  • Entropy-balanced
  • Multi-site

Main finding

As reported in the abstract

CM vs No CMOdds ratio (95% CI)
Unadjusted multivariable logistic regression
1(0.89–1.11)
Propensity weighting
0.93(0.83–1.05)
Entropy balancing
0.94(0.83–1.05)

Observational data: associations, not effects.

Further findings

Persistent AKI, intensive care unit (ICU) subgroup (subgroup)

Similar results in those admitted to the ICU

Initiation of dialysis · within 180 days

Dialysis initiated in whole cohort
5.4%
No association between contrast media (CM) and increased risk of dialysis

Cohort characteristics

Admitted to ICU
12.8%
CM administered
18.4%
AKI resolved before discharge
69.1%

Original publication

Renal outcomes following intravenous contrast administration in patients with acute kidney injury: a multi-site retrospective propensity-adjusted analysis. Intensive Care Med. Published 30 January 2023. doi:10.1007/s00134-022-06966-w

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.